Back to search results

Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma

Abroad (travel likely)RecruitingPHASE1

Conditions

Recurrent Multiple Myeloma · Refractory Multiple Myeloma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States

    Contact: Study coordinator (Site Public Contact) · 855-776-0015
    Contact: Principal Investigator (Ricardo D. Parrondo)

  • Smilow Cancer Hospital-Derby Care Center, Derby, Connecticut, United States

    Contact: Study coordinator (Site Public Contact) · canceranswers@yale.edu · 203-785-5702
    Contact: Principal Investigator (Elan Gorshein)

  • Smilow Cancer Hospital Care Center - Guilford, Guilford, Connecticut, United States

    Contact: Study coordinator (Site Public Contact) · canceranswers@yale.edu · 203-785-5702
    Contact: Principal Investigator (Elan Gorshein)

  • Yale University, New Haven, Connecticut, United States

    Contact: Study coordinator (Site Public Contact) · canceranswers@yale.edu · 203-785-5702
    Contact: Principal Investigator (Elan Gorshein)

  • Yale-New Haven Hospital North Haven Medical Center, North Haven, Connecticut, United States

    Contact: Study coordinator (Site Public Contact) · canceranswers@yale.edu · 203-785-5702
    Contact: Principal Investigator (Elan Gorshein)

  • Mayo Clinic in Florida, Jacksonville, Florida, United States

    Contact: Study coordinator (Site Public Contact) · 855-776-0015
    Contact: Principal Investigator (Ricardo D. Parrondo)

  • Moffitt Cancer Center, Tampa, Florida, United States

  • University of Kansas Cancer Center, Kansas City, Kansas, United States

    Contact: Study coordinator (Site Public Contact) · KUCC_Navigation@kumc.edu · 913-588-3671
    Contact: Principal Investigator (Jeries Kort)

  • University of Kansas Cancer Center-Overland Park, Overland Park, Kansas, United States

    Contact: Study coordinator (Site Public Contact) · KUCC_Navigation@kumc.edu · 913-588-3671
    Contact: Principal Investigator (Jeries Kort)

  • University of Kansas Hospital-Westwood Cancer Center, Westwood, Kansas, United States

    Contact: Study coordinator (Site Public Contact) · KUCC_Navigation@kumc.edu · 913-588-3671
    Contact: Principal Investigator (Jeries Kort)

  • Mayo Clinic in Rochester, Rochester, Minnesota, United States

    Contact: Study coordinator (Site Public Contact) · 855-776-0015
    Contact: Principal Investigator (Ricardo D. Parrondo)

  • Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

    Contact: Study coordinator (Site Public Contact) · Jamesline@osumc.edu · 800-293-5066
    Contact: Principal Investigator (Srinivas S. Devarakonda)

  • University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States

    Contact: Study coordinator (Site Public Contact) · ou-clinical-trials@ouhsc.edu · 405-271-8777
    Contact: Principal Investigator (Muhammad Salman Faisal)

  • VCU Massey Comprehensive Cancer Center, Richmond, Virginia, United States

    Contact: Study coordinator (Site Public Contact) · CTOclinops@vcu.edu · 804-628-6430
    Contact: Principal Investigator (Hashim Mann)
Study leads

  • Ricardo D Parrondo

    Principal Investigator

    Dana-Farber - Harvard Cancer Center LAO

View source on ClinicalTrials.gov(opens in a new tab)